BUZZ-Scholar Rock falls on FDA review; analysts flag optimistic expectations

Reuters01-12

BUZZ-<a href="https://laohu8.com/S/SRRK">Scholar Rock</a> falls on FDA review; analysts flag optimistic expectations

** Shares of drug developer Scholar Rock SRRK.O down 2.5% at $41.12

** SRRK says U.S. FDA has scheduled meeting with third-party manufacturing facility, Catalent Indiana, part of Novo Nordisk NOVOb.CO, in early 2026 to discuss progress of remediation efforts

** Expects resubmission of marketing application of apitegromab for muscle weakness and U.S. launch following FDA's potential approval in 2026

** In September, agency declined to approve apitegromab citing issues at the facility

** "Catalent site could take time to be resolved" - Truist analyst Srikripa Devarakonda

** Adds: "This is in-line with our model baseline assumptions of H1 2026 or mid-2026 submission of BLA and 2027 launch"

** SRRK expects to submit a supplemental application for apitegromab to treat facioscapulohumeral muscular dystrophy with second site later in 2026

** Stock fell 7.3% in 2025

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602541650?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 23:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602541650","market":"nz","top_or_hot":-1,"title":"BUZZ-Scholar Rock falls on FDA review; analysts flag optimistic expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/SRRK\">Scholar Rock</a> falls on FDA review; analysts flag optimistic expectations</title></head><body><p>** Shares of drug developer Scholar Rock <span>SRRK.O</span> down 2.5% at $41.12</p><p>** SRRK says U.S. FDA has scheduled meeting with third-party manufacturing facility, <a href=\"https://laohu8.com/S/CTLT\">Catalent</a> Indiana, part of <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> <span>NOVOb.CO</span>, in early 2026 to discuss progress of remediation efforts</p><p>** Expects resubmission of marketing application of apitegromab for muscle weakness and U.S. launch following FDA's potential approval in 2026  </p><p>** In September, agency <span>declined to approve</span> apitegromab citing issues at the facility</p><p>** \"Catalent site could take time to be resolved\" - Truist analyst Srikripa Devarakonda</p><p>** Adds: \"This is in-line with our model baseline assumptions of H1 2026 or mid-2026 submission of BLA and 2027 launch\"</p><p>** SRRK expects to submit a supplemental application for apitegromab to treat facioscapulohumeral muscular dystrophy with second site later in 2026</p><p>** Stock fell 7.3% in 2025</p><p>(Reporting by Siddhi Mahatole)</p><p>((siddhi.mahatole@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Scholar Rock falls on FDA review; analysts flag optimistic expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Scholar Rock falls on FDA review; analysts flag optimistic expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 23:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/SRRK\">Scholar Rock</a> falls on FDA review; analysts flag optimistic expectations</title></head><body><p>** Shares of drug developer Scholar Rock <span>SRRK.O</span> down 2.5% at $41.12</p><p>** SRRK says U.S. FDA has scheduled meeting with third-party manufacturing facility, <a href=\"https://laohu8.com/S/CTLT\">Catalent</a> Indiana, part of <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> <span>NOVOb.CO</span>, in early 2026 to discuss progress of remediation efforts</p><p>** Expects resubmission of marketing application of apitegromab for muscle weakness and U.S. launch following FDA's potential approval in 2026  </p><p>** In September, agency <span>declined to approve</span> apitegromab citing issues at the facility</p><p>** \"Catalent site could take time to be resolved\" - Truist analyst Srikripa Devarakonda</p><p>** Adds: \"This is in-line with our model baseline assumptions of H1 2026 or mid-2026 submission of BLA and 2027 launch\"</p><p>** SRRK expects to submit a supplemental application for apitegromab to treat facioscapulohumeral muscular dystrophy with second site later in 2026</p><p>** Stock fell 7.3% in 2025</p><p>(Reporting by Siddhi Mahatole)</p><p>((siddhi.mahatole@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRRK","symbol_name":"Scholar Rock Holding Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nL4N3YD18H:1","article_id":"2602541650","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602541650","pubTimestamp":1768231720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Scholar Rock falls on FDA review; analysts flag optimistic expectations** Shares of drug developer Scholar Rock SRRK.O down 2.5% at $41.12** SRRK says U.S. FDA has scheduled meeting with third-pa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SRRK":"Scholar Rock Holding Corp","BK4139":"生物科技"},"translate_title":"BUZZ-Scholar Rock因FDA审查而落败；分析师表示乐观预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRRK":0.9},"content_text":"BUZZ-Scholar Rock falls on FDA review; analysts flag optimistic expectations** Shares of drug developer Scholar Rock SRRK.O down 2.5% at $41.12** SRRK says U.S. FDA has scheduled meeting with third-party manufacturing facility, Catalent Indiana, part of Novo Nordisk NOVOb.CO, in early 2026 to discuss progress of remediation efforts** Expects resubmission of marketing application of apitegromab for muscle weakness and U.S. launch following FDA's potential approval in 2026  ** In September, agency declined to approve apitegromab citing issues at the facility** \"Catalent site could take time to be resolved\" - Truist analyst Srikripa Devarakonda** Adds: \"This is in-line with our model baseline assumptions of H1 2026 or mid-2026 submission of BLA and 2027 launch\"** SRRK expects to submit a supplemental application for apitegromab to treat facioscapulohumeral muscular dystrophy with second site later in 2026** Stock fell 7.3% in 2025(Reporting by Siddhi Mahatole)((siddhi.mahatole@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602541650","isCrawlerRequest":true}